ADIA Nutrition, Inc. Reports Strong Revenue Growth and Operational Momentum for First Quarter 2026
Winter Park, Florida--(Newsfile Corp. - May 15, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in advanced nutrition and regenerative health solutions, today announced its 3rd party reviewed financial results for the first quarter ended March 31, 2026, highlighting significant year-over-year revenue growth and continued expansion of its biologics and medical procedures segments.
Healthcare and Hospitals, Health
2026-05-15 7:59 AM EDT | Adia Nutrition Inc.
AllStar Global Brands Announces Strategic Partnership with Riccione Femminile Calcio
Ontario and Riccione, Italy--(Newsfile Corp. - May 14, 2026) - AllStar Global Brands (OTCID: ALST) ("ASGB") is pleased to announce that an agreement has been reached to acquire a 60% ownership stake in Riccione Femminile Calcio for €50,000, marking the beginning of a long-term strategic partnership focused on developing women's football and international player pathways. As part of the agreement, ASGB will provide financial assistance, operational support, and access to d
Healthcare and Hospitals, Retail, Health
2026-05-14 10:37 AM EDT | Allstar Health Brands, Inc.
Conexeu Sciences Unveils Defining Commitment: Architecting Bioregeneration(TM)
Reno, Nevada--(Newsfile Corp. - May 14, 2026) - Conexeu Sciences Inc. (the "Company" or "Conexeu") a medical device company advancing regenerative medicine through its patented bioregenerative extracellular matrix platform, today unveiled a new defining identity: Architecting Bioregeneration™.
Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-14 8:30 AM EDT | Conexeu Sciences Inc.
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 25,347,133 common shares, representing 69.754% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in th
Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-13 8:41 PM EDT | Profound Medical Corp.
TelyRx Announces First Quarter 2026 Financial Results
Clearwater, Florida--(Newsfile Corp. - May 12, 2026) - TelyRx Holdings Inc. (TSX: TELY) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced financial results for the first quarter ended March 31, 2026. All dollar amounts are expressed in U.S. dollars. Highlights for the First Quarter of 2026 Revenue increased to $19.4 million, compared to $14.3 million in Q
Healthcare and Hospitals, Health
2026-05-12 5:57 PM EDT | TelyRx
Kovo+ Holdings Inc. Appoints Matthew Woodin as Chief Financial Officer
Calgary, Alberta--(Newsfile Corp. - May 12, 2026) - Kovo+ Holdings Inc. (TSXV: KOVO) ("Kovo" or the "Company") today announced the appointment of Matthew Woodin as Chief Financial Officer, effective May 12, 2026, subject to approval from the TSXV. Woodin joins Kovo with more than 15 years of financial leadership experience in the healthcare sector, spanning provider organizations, payer systems, and multi-state operations. He has served in senior executive roles overseeing strategic fin
Technology, Healthcare and Hospitals, Internet Technology
2026-05-12 5:30 PM EDT | Kovo+ Holdings Inc.
TelyRx to Host First Quarter 2026 Financial Results Conference Call on Wednesday, May 13, 2026 at 8:30 am ET
Clearwater, Florida--(Newsfile Corp. - May 12, 2026) - TelyRx Holdings Inc. (TSX: TELY) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced it will host a conference call and webcast to discuss its first quarter 2026 financial results on Wednesday, May 13, 2026, at 8:30 a.m. Eastern Time (ET). The Company expects to report its first quarter 2026 financial results for the period ended March 31, 2026, after market cl
Healthcare and Hospitals, Health
2026-05-12 10:45 AM EDT | TelyRx
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - May 12, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing tec
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-12 7:00 AM EDT | Phio Pharmaceuticals Corp.
Resverlogix Announces One-Year Extension of Debenture
Calgary, Alberta--(Newsfile Corp. - May 11, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a one-year extension of the Company's US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of accrued interest thereon), extending the maturity date to May 13, 2027. In connection with the extension, the interest rate has been amended from 18% to 20% per annum, commencing on May 14, 2026. "
Technology, Biotechnology, Healthcare and Hospitals
2026-05-11 5:15 PM EDT | Resverlogix Corp.
FONAR Announces Financial Results for Fiscal 2026 Third Quarter and Nine-Month Period
Net Income decreased 25% to $2.3 million for the quarter ended March 31, 2026 as compared to the quarter ended March 31, 2025. Income from Operations for the quarter ended March 31, 2026 decreased 33% to $2.4 million as compared to the quarter ended March 31, 2025. Diluted Net Income Per Common Share Available to Common Stockholders decreased 35% to $0.24 per share for the quarter ended March 31, 2026 as compared to
Technology, Healthcare and Hospitals
2026-05-11 4:15 PM EDT | Fonar Corporation
ADIA Nutrition Announces IRB Approval of All Four Clinical Studies and Registration of Kidney Health Study on ClinicalTrials.gov
Winter Park, Florida--(Newsfile Corp. - May 11, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a publicly traded company advancing regenerative medicine through its subsidiary Adia Med of Winter Park, LLC, today announced that all four of its planned clinical studies have received Institutional Review Board (IRB) approval. This milestone enables the continued execution and launch of human trials evaluating the safety and potential efficacy of the Company's proprietary AdiaVita™ stem cell a
Healthcare and Hospitals, Health
2026-05-11 10:04 AM EDT | Adia Nutrition Inc.
Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - May 11, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported first quarter 2026 results and landmark achievements that advance the Company another step closer toward commercialization of its investigational Acclaim® cochlear implant. "The first quarter of 2026 marked a transformative period for Envoy Medical, highlighted
Biotechnology, Healthcare and Hospitals
2026-05-11 8:00 AM EDT | Envoy Medical, Inc.
CardioComm Announces Adoption of Quarterly Reporting Exemption Under Coordinated Blanket Order 51-933
Toronto, Ontario--(Newsfile Corp. - May 8, 2026) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a leader in consumer heart monitoring, remote patient monitoring, and medical electrocardiogram ("ECG") software solutions, announces that it has elected to rely on Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers and move to semi-annual financial reporting ("SAR"). Coordinated Blanket Order 51-933 allow
Technology, Healthcare and Hospitals, Health
2026-05-08 4:01 PM EDT | CardioComm Solutions, Inc.
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today reported its financial results for the quarter ended March 31, 2026, and provided a busine
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-07 4:05 PM EDT | Phio Pharmaceuticals Corp.
HEALWELL Delivers 316% Revenue Growth and Increasing Customer Traction in Q1-2026
HEALWELL achieved quarterly revenue from continuing operations of $33.2 million in Q1-2026, an increase of 316% compared to revenue of $8.0 million generated in Q1-2025. Revenue growth in the quarter was largely driven by the Orion Health acquisition and organic growth of the Company's AI division. HEALWELL reported positive Adjusted EBITDA of $0.7 million in Q1-2026, compared to an Adjusted EBITDA loss of $2.3 million in Q1-2025, representing a year-over-year improvem
Technology, Healthcare and Hospitals
2026-05-07 4:00 PM EDT | HEALWELL AI
WELL Health Delivers Record Q1-2026 with Canadian Clinics Run Rate Exceeding $500M and Revenue Up 25% to $368M
WELL achieved quarterly revenues of $368.3 million in Q1-2026, an increase of 25% as compared to Q1-2025 driven by organic growth, acquisitions and the inclusion of HEALWELL results in WELL's consolidated financial reporting. WELL achieved Adjusted EBITDA(1) of $43.1 million in Q1-2026, an increase of 56% as compared to Q1-2025, representing an Adjusted EBITDA Margin(1) of 12%. Canadian Patient Services revenues(4) increased by 30% to $130
Technology, Computer Software, Healthcare and Hospitals, Health
2026-05-07 4:00 PM EDT | WELL Health Technologies Corp.
CareRx Announces Q2 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - May 6, 2026) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company"), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, today announced that the Company's Board of Directors has declared a dividend of CAD$0.02 per outstanding common share of the Company ("Common Shares"), payable on July 9, 2026, to holders of record of Common Shares as of the close of business on June 23, 2026.
2026-05-06 7:23 PM EDT | CareRx Corporation
CareRx Reports Results for The First Quarter of 2026
Toronto, Ontario--(Newsfile Corp. - May 6, 2026) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company"), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, today reported its financial results for the first quarter ended March 31, 2026. Highlights for the First Quarter of 2026 Average Beds Serviced[1] increased to 92,036 in Q1 2026 from 87,675 Average Beds Serviced
2026-05-06 7:21 PM EDT | CareRx Corporation
Theralase(R) Announces $4 Million Brokered LIFE Offering
Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and v
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-05-05 7:10 PM EDT | Theralase Technologies Inc.
NewOrg to Present on AI for Nonprofits at PowerNET 2026 Conference
Washington, D.C.--(Newsfile Corp. - May 5, 2026) - NewOrg is attending and exhibiting at PowerNET 2026, taking place May 4-7 in Toronto, Canada. As part of this year's conference, NewOrg is co-presenting alongside the Workforce Professionals Training Institute on the evolving role of AI in human services. Hosted by the Network of Jewish Human Service Agencies, PowerNET is an annual conference that brings together nonprofit leaders, practitioners, and technology partners to explore emerg
Computer Software, Healthcare and Hospitals, Housing, Aboriginal / Indigenous
2026-05-05 12:00 PM EDT | NewOrg Management System Inc